TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19675505
Drug: Tapering down
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering down of combined estrogen plus progestogen therapy (EPT)
Study: 19675505
Drug: Abrupt discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt discontinuation of combined estrogen plus progestogen therapy (EPT)
Study: 17395393
Drug: CO2 inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 inhalation test (exam group)
Study: 17395393
Drug: CO2 inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 inhalation test (non-exam group)
Study: 17395393
Drug: CO2 inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 inhalation test (both groups)
Study: 7973660
Drug: Cholinergic antagonist,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinergic antagonist, tropicamide, placed in the eyes of patients with Alzheimer's disease
Study: 2637679
Drug: Morphine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine administered via buccal route (controlled release formulation)
Study: 2637679
Drug: Morphine-3-glucuronide and
Normalized name: MENTHOL GLUCURONIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-3-glucuronide and morphine-6-glucuronide
Study: 29910016
Drug: In-session commitment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-session commitment statements (strength, frequency, and slope of strength) made in two therapy sessions
Study: 29910016
Drug: Low pre-treatment
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low pre-treatment commitment to abstain and increasing commitment strength across a session
Study: 26046730
Drug: Intracoronary BMMC
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary BMMC injection
Study: 26046730
Drug: G‐CSF mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF mobilization (10 μg/kg/day subcutaneously for 5 days)
Study: 26046730
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BMMC injection plus G‐CSF
Study: 23239554
Drug: Cholinesterase inhibitor
Normalized name: Acetylcholinesterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitor treatment for 6 months
Study: 21198228
Drug: CBT4CBT (computer-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT4CBT (computer-based cognitive-behavioral therapy)
Study: 16556794
Drug: Oral proton
Normalized name: Protonix Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral proton pump inhibitor (pantoprazole 20 mg)
Study: 12967069
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic agent
Study: 12967069
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of topical anesthetic and pressure anesthesia
Study: 12967069
Drug: No site
Approvals — FDA: no, EMA: no, PMDA: no
Description: No site preparation (non-placebo control)
Study: 10741595
Drug: Rapid induction
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid induction analgesia (RIA) conducted twice on 15 patients
Study: 8543503
Drug: Meropenem monotherapy
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem monotherapy
Study: 8723449
Drug: Ceftazidime plus
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime plus amikacin combination therapy
Study: 23044498
Drug: 6% hydroxyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxyl ethyl starch (HES) solution (Voluven)
Study: 20819983
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication plus psychosocial intervention
Study: 12474761
Drug: Medications for
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications for osteoporosis treatment
Study: 1724102
Drug: Prostacyclin (PGI2)
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacyclin (PGI2) infusion of 10 or 20 ng/kg/min
Study: 1724102
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin substitution
Study: 1724102
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prostacyclin and aprotinin
Study: 6991541
Drug: Oral zomepirac
Normalized name: zomepirac
DrugBank: Zomepirac (DB04828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zomepirac 100 mg
Study: 6991541
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine 16 mg
Study: 6991541
Drug: Oral zomepirac
Normalized name: zomepirac
DrugBank: Zomepirac (DB04828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zomepirac
Study: 26132512
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) application (AIGaAs diode, 810 nm, 100 mW, 2J/cm(2), 15 seconds per point)
Study: 21289587
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 15 mg/kg body weight intravenously before incision
Study: 11282177
Drug: Aerosolized rhDNase
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized rhDNase (2.5 mg daily) for 3 months
Study: 9467148
Drug: Immediate diagnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate diagnosis and treatment
Study: 25119609
Drug: IIV3-HD (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV3-HD (60 μg of hemagglutinin per strain)
Study: 25119609
Drug: IIV3-SD (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV3-SD (15 μg of hemagglutinin per strain)
Study: 19032175
Drug: Clamping method
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clamping method with BrAC-guided adjustments to maintain stable BrAC levels of 0.6 g l(‐1)
Study: 19032175
Drug: Two-step prekinetic
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-step prekinetic procedure with a target BrAC of 0.65 g l(‐1)
Study: 12765659
Drug: Homemade liquid
Normalized name: Welmedix Homecare Pro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homemade liquid supplement
Study: 10589806
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus subgingival application of metronidazole 25% dental gel (Elyzol) 5x during 10 days
Study: 1755555
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (IN) 0.15 mg.kg‐1
Study: 1755555
Drug: Intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular midazolam (IM) 0.15 mg.kg‐1
Study: 31818232
Drug: Curcumin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (250 mg/day)
Study: 31818232
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 mg/day)
Study: 28560655
Drug: BioResponse DIM®
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioResponse DIM® (BR-DIM) at 150 mg twice daily
Study: 9679572
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with oral fluorouracil
Study: 8023998
Drug: Arginine vasopressin
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine vasopressin (AVP) infusion (plasma AVP 16-20 pg/ml)
Study: 2920304
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg, three times daily
Study: 2920304
Drug: Disopyramide 200
Normalized name: disopyramide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide 200 mg single dose, three days after propranolol discontinuation
Study: 2920304
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propranolol and disopyramide
Study: 1093108
Drug: Methylphenidate (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (dosage range: 0.2 to 1.9 mg/kg)
Study: 16339502
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE) (0.625 mg/d)
Study: 16339502
Drug: CEE plus
Normalized name: Ecee Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE plus medroxyprogesterone acetate (MPA) (2.5 mg/d)
Study: 6876944
Drug: Nicergoline (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (30 mg)
Study: 6876944
Drug: Nicergoline (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (15 mg) and Propranolol (20 mg)
Study: 30935515
Drug: 2000 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg/day dried ginger powder for 12 weeks
Study: 27179731
Drug: Newer generation
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer generation permanent polymer-coated drug-eluting stents (DES)
Study: 25199531
Drug: Nine-month regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine-month regimen including clofazimine and high-dose moxifloxacin (can be extended to 11 months if needed)
Study: 22897540
Drug: Young Parenthood
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Young Parenthood Program (YPP), a 10-week counseling program administered during pregnancy
Study: 17980021
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A practices (didactic training and course materials in oral health screening, referral, counseling, and application of fluoride varnish)
Study: 17980021
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B practices (same as Group A + weekly conference calls providing advice and support)
Study: 15817595
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg taken daily for 5 years
Study: 374692
Drug: Parent-administered behavior
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-administered behavior checklist (regardless of group assignment)
Study: 374692
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of kryptopyrrole
Study: 23132732
Drug: Standardized humor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized humor therapy group
Study: 19856521
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of A/Vietnam/1194/2004 given 6 months apart
Study: 19856521
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of A/Vietnam/1194/2004 given 21 days apart
Study: 19856521
Drug: A/Indonesia/05/2005 booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/Indonesia/05/2005 booster dose after one primary dose of A/Vietnam/1194/2004
Study: 16740843
Drug: Iron-fortified rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified rice meal (approximately 15 mg of iron per day as ferric pyrophosphate)
Study: 15634526
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose impulsion chemotherapy (HDIC)
Study: 15634526
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose density chemotherapy (LDDC)
Study: 8990427
Drug: 15-methyl prostaglandin
Normalized name: 15(S)-15-Methyl Prostaglandin F2α
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-methyl prostaglandin F2 alpha (250 micrograms, intramuscularly every 20 minutes, maximum three doses)
Study: 8990427
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline, intramuscularly every 20 minutes, maximum three doses)
Study: 3525273
Drug: Oral ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ketoconazole (400 mg for 5 days)
Study: 3525273
Drug: Topical miconazole
Normalized name: miconazole Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical miconazole (1200 mg a single dose)
Study: 21558457
Drug: Isoniazid 10
Normalized name: isoniazid 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid 10 to 20 mg/kg/d orally
Study: 12813116
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) plus SSRIs when indicated, initiated at a median of 17 days after MI for a median of 11 sessions over 6 months.
Study: 12813116
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) plus SSRIs when indicated
Study: 8497020
Drug: Imagery training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imagery training programme (visual and kinaesthetic imagery, internal and external perspectives), 6 weeks, bi-weekly sessions of 15 min each.
Study: 8497020
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (competitive strategy unrelated to performance task), 6 weeks, bi-weekly sessions of 15 min each.
Study: 3576125
Drug: Hourly aspiration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly aspiration of gastric juice
Study: 23866835
Drug: Granule group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granule group at 10 grams, three times daily (G10 group)
Study: 23866835
Drug: Granule group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granule group at 20 grams, three times daily (G20 group)
Study: 14586349
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (100 microg every 6 hours to a maximum of two doses)
Study: 16019795
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (1.5 g/day)
Study: 16019795
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (3.0 g/day)
Study: 16019795
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (1.5 g/day and 3.0 g/day)
Study: 10515023
Drug: Cold intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold intraoperative wound irrigation with a cold (18 C) 5% bacitracin solution for 5 minutes and postoperative wound cooling with a microtemperature pump for 24 hours.
Study: 10515023
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative care without additional hypothermic therapy (control group).
Study: 1837763
Drug: Short wave
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short wave therapy (460 MHz, 50‐60 W, for 8‐20 minutes)
Study: 14748864
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (screening and treatment for depression by resident physicians)
Study: 9213940
Drug: Taping and
Normalized name: Baza Cleanse and Protect Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taping and oral NSAID proglumetacine b.i.d. (26 patients)
Study: 9213940
Drug: Taping and
Normalized name: Baza Cleanse and Protect Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taping and oral placebo b.i.d. (22 patients)
Study: 8424422
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg intravenously every 8 hours for nine doses
Study: 23438483
Drug: Adalimumab weekly
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab weekly dosing
Study: 23438483
Drug: Adalimumab every
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab every other week (eow) dosing
Study: 21617556
Drug: Nerve block
Normalized name: Nerve Block Tray 22g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve block anesthesia at the wrist with 1% lidocaine followed by standard injection
Study: 21617556
Drug: Standard injection
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard injection alone using 1-needle 2-syringe technique with 0.5 mL 1% lidocaine and 20 mg triamcinolone acetonide
Study: 18433305
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D supplementation (2000 mg calcium and 800 IU vitamin D/d)
Study: 17202633
Drug: Miltefosine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miltefosine (2.5 mg/Kg/day, orally, o.d. or b.i.d., max 100 mg)
Study: 17202633
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (1 mg/Kg/day, total 15 mg/Kg)
Study: 12783417
Drug: Interferon beta1a
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta1a 22 microg subcutaneously once weekly
Study: 10189772
Drug: Experimental form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental form of therapy of indeterminate benefit
Study: 10189772
Drug: Randomized clinical
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized clinical trial of two therapies
Study: 8610312
Drug: Increased common
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased common carotid intima-media thickness (CC-IMT)
Study: 1928569
Drug: Levo-praziquantel (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levo-praziquantel (20 mg/kg)
Study: 6651596
Drug: 10% viscous
Normalized name: POVIDONE IODINE 10% VISCOUS GAUZE PAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% viscous solution of phenylephrine hydrochloride
Study: 6651596
Drug: 2.5% aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% aqueous solution of phenylephrine hydrochloride
Study: 30678193
Drug: Tart cherry
Normalized name: Tart Cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tart cherry juice (480 mL daily for 12 weeks)
Study: 23839181
Drug: Topical brimonidine
Normalized name: brimonidine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical brimonidine tartrate gel 0.5%
Study: 22379915
Drug: Ketoprofen combined
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen combined with intramuscular injection of trimeperidine
Study: 16461817
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (STD)
Study: 11679455
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group received insulin treatment
Study: 11679455
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group received insulin if AC >70th percentile and/or FPG >120 mg/dl
Study: 11679455
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (infants of women who did not receive insulin)
Study: 9447368
Drug: Dihydralazine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine (5 mg, repeated every 20 min up to 4 doses)
Study: 9447368
Drug: Ketanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (10 mg, repeated every 20 min up to 4 doses)
Study: 8199822
Drug: Alkali citrate
Normalized name: alkali blite pollen extract
DrugBank: Suaeda moquinii pollen (DB10953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkali citrate therapy (group II, n = 25)
Study: 29630549
Drug: Propolis (0.83
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis (0.83 g, n=30)
Study: 24068048
Drug: Recovery of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery of intramuscular phosphocreatine concentration
Study: 21417560
Drug: Continuous COC
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous COC (levonorgestrel [LNG] 90 μg/ethinylestradiol [EE] 20 μg)
Study: 21417560
Drug: Cyclic COC
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic COC (LNG 100 μg/EE 20 μg, 21/7 days pattern)
Study: 1486675
Drug: Intramuscular artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular artemether plus oral mefloquine
Study: 1486675
Drug: Intravenous artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous artesunate plus oral mefloquine
Study: 1486675
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine plus oral tetracycline
Study: 7011353
Drug: Amoxycillin 250
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 250 mg or 500 mg, orally three times daily for seven days
Study: 7011353
Drug: Ampicillin 250
Normalized name: ampicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 250 mg or 500 mg, orally three times daily for seven days
Study: 7011353
Drug: Amoxycillin and
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin and Ampicillin (both doses)
Study: 30859185
Drug: Ivermectin 100
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 100 or 200 μg/kg for PSAC; 200, 400 or 600 μg/kg for SAC
Study: 23020829
Drug: Routine iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine iron group (n=2184) received 60 mg of ferrous sulphate plus 400 μg of folic acid daily